share_log

ARS Pharmaceuticals Q4 2023 GAAP EPS $(0.57) Misses $(0.14) Estimate

Moomoo 24/7 ·  Mar 21 16:17

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.14) by 307.14 percent.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment